Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses LXEO in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named LXEO in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| R. Nolan Townsend | $632,700 | $0 | $1,493,488 | $1,165,982 | $347,985 | $0 | $10,785 | $3,650,940 |
| Chief Executive Officer and Director | ||||||||
| Jenny Robertson | 459,600 | 0 | 485,613 | 407,444 | 183,840 | 0 | 609,386 | 2,145,883 |
| Former Chief Legal Officer | ||||||||
| Louis Tamayo | 181,818 | 0 | 215,550 | 1,066,013 | 197,760 | 0 | 4,774 | 1,665,915 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| R. Nolan Townsend | $3,650,940 | $4,375,248 | — | −724,308 |
| Jenny Robertson | 2,145,883 | 2,485,110 | — | −339,227 |
| Louis Tamayo | 1,665,915 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| R. Nolan Townsend | RSU | 67,000 | — | $665,310 |
| R. Nolan Townsend | RSU | 103,750 | — | 1,030,238 |
| Louis Tamayo | RSU | 45,000 | — | 446,850 |
| Jenny Robertson | RSU | 36,250 | — | 359,963 |
| R. Nolan Townsend | RSU | 24,607 | — | 244,348 |
| Jenny Robertson | RSU | 20,100 | — | 199,593 |
| Jenny Robertson | RSU | 13,357 | — | 132,635 |
| R. Nolan Townsend | Option | 136,716 | 14.48 | — |
| R. Nolan Townsend | Option | 207,500 | 7.33 | — |
| Louis Tamayo | Option | 280,000 | 4.79 | — |
| Jenny Robertson | Option | 74,216 | 14.48 | — |
| Jenny Robertson | Option | 72,500 | 7.33 | — |
The provided text does not contain a specific Compensation Discussion & Analysis (CD&A) narrative section detailing the company's pay philosophy, but indicates a compensation structure based on base salary, annual discretionary cash bonuses, and long-term equity incentives (options, RSUs, and PRSUs) designed to align executive interests with stockholder value.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Steven Altschuler, M.DIndependent · Board Chair · Compensation · Science and Technology | $82,000 | $0 | $81,361 | $0 | $0 | $163,361 |
| Paula HJ CholmondeleyIndependent · Audit (Chair) | 59,614 | 0 | 81,361 | 0 | 0 | 140,975 |
| Reinaldo DiazIndependent · Audit · Compensation (Chair) | 59,500 | 0 | 81,361 | 0 | 0 | 140,861 |
| Mette Kirstine AggerIndependent · Audit · Nominating and Corporate Governance (Chair) | 59,500 | 0 | 81,361 | 0 | 0 | 140,861 |
| Brenda Cooperstone, M.DIndependent · Nominating and Corporate Governance · Science and Technology (Chair) | 58,000 | 0 | 81,361 | 0 | 0 | 139,361 |
| Tim Van HauwermeirenIndependent · Nominating and Corporate Governance | 46,000 | 0 | 74,579 | 0 | 0 | 120,579 |
| Tolga TangulerIndependent · Compensation | 41,386 | 0 | 47,459 | 0 | 0 | 88,845 |
| R. Nolan TownsendEmployee director | — | — | — | — | — | 0 |
| Dr. Sepp-LorenzinoIndependent · Science and Technology · Newly elected | — | — | — | — | — | — |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 12,000 / 12,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $406,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $406,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Lexeo Therapeutics | 2025 | R. Nolan Townsend | $632,700 | $1,493,488 | $1,165,982 | $347,985 | $3,650,940 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, R. Nolan Townsend | DEF 14A | 2026-04-30 | 0001193125-26-193930 | Section “Summary Compensation Table” · page 21. As printed: 3,650,940. Filing ↗machine: r2 · c21 · span 463876–463885 |
| 2 | Section 01, Jenny Robertson | DEF 14A | 2026-04-30 | 0001193125-26-193930 | Section “Summary Compensation Table” · page 21. As printed: 2,145,883. Filing ↗machine: r6 · c21 · span 496339–496348 |
| 3 | Section 01, Louis Tamayo | DEF 14A | 2026-04-30 | 0001193125-26-193930 | Section “Summary Compensation Table” · page 21. As printed: 1,665,915. Filing ↗machine: r4 · c21 · span 480172–480181 |
| 4 | Section 08, Steven Altschuler, M.D | DEF 14A | 2026-04-30 | 0001193125-26-193930 | Section “Director Compensation”. As printed: 163,361. Filing ↗machine: span 352400–352609 |
| 5 | Section 08, Paula HJ Cholmondeley | DEF 14A | 2026-04-30 | 0001193125-26-193930 | Section “Director Compensation”. As printed: 140,975. Filing ↗machine: span 360063–360272 |
| 6 | Section 08, Reinaldo Diaz | DEF 14A | 2026-04-30 | 0001193125-26-193930 | Section “Director Compensation”. As printed: 140,861. Filing ↗machine: span 375384–375593 |
| 7 | Section 08, Mette Kirstine Agger | DEF 14A | 2026-04-30 | 0001193125-26-193930 | Section “Director Compensation”. As printed: 140,861. Filing ↗machine: span 344735–344944 |
| 8 | Section 08, Brenda Cooperstone, M.D | DEF 14A | 2026-04-30 | 0001193125-26-193930 | Section “Director Compensation”. As printed: 139,361. Filing ↗machine: span 367729–367938 |
| 9 | Section 08, Tim Van Hauwermeiren | DEF 14A | 2026-04-30 | 0001193125-26-193930 | Section “Director Compensation”. As printed: 120,579. Filing ↗machine: span 390701–390910 |
| 10 | Section 08, Tolga Tanguler | DEF 14A | 2026-04-30 | 0001193125-26-193930 | Section “Director Compensation”. As printed: 88,845. Filing ↗machine: span 383040–383248 |
| 11 | Section 08, R. Nolan Townsend | DEF 14A | 2026-04-30 | 0001193125-26-193930 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 12 | Section 08, Dr. Sepp-Lorenzino | DEF 14A | 2026-04-30 | 0001193125-26-193930 | Section “Director Compensation”. As printed: —. Filing ↗ |
| 13 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 14 | Section 09b board cost (computed) | Computed | — | computed | Cash 406,000 + equity 0 + all other 0 = 406,000, summed across the director compensation table rows.machine: formula: Σ = 406,000 |
| 15 | Lexeo Therapeutics (subject), Section 10b CEO total | DEF 14A | 2026-04-30 | 0001193125-26-193930 | CEO total compensation as printed in Lexeo Therapeutics's own proxy. As printed: 3,650,940. Filing ↗machine: r2 · c21 · span 463876–463885 |